TC-PMY-116*Invasive Pulmonary Aspergillosis (IPA)
TC-PMY-119*Allergic Bronchopulmonary Aspergillosis (ABPA)
TC-PMY-121*Esophageal Candidiasis (EC)
TC-PMY-123* Pulmonary Cryptococcosis (PC)

*We hold rights to develop these molecules pursuant to a material transfer agreement with a drug-design firm.

We are developing a novel inhalation therapeutic for treating fungal infections in immunocompromised patients.

Invasive Pulmonary Aspergillosis

Invasive Pulmonary Aspergillosis (IPA) is caused by Aspergillus and is the most common mold infection in immunocompromised hosts. It becomes very aggressive and rapidly spreads throughout the lungs and often through the bloodstream to the brain, heart, liver, and kidneys. The most common risk factors for infection include neutropenia and glucocorticoid use, hematopoietic cell transplantation, solid organ transplantation (particularly lung transplantation), the use of biologic agents, pulmonary diseases, and critical illness. Rapid institution of voriconazole  through the IV route is considered optimal therapy. TC-PMY-116 has been designed for targeted delivery into the lungs at drastically lower dosage to address the adverse events that can emerge from long-term systemic use.

Allergic Bronchopulmonary Aspergillosis

Allergic Bronchopulmonary Aspergillosis (ABPA) that afflicts people who have asthma or cystic fibrosis and develop a chronic allergic reaction with cough, wheezing, and fever if Aspergillus colonizes the lining of their airways. Complications that result from delay in treatment for ABPA are pulmonary fibrosis, bronchiectasis with chronic sputum production, and severe persistent asthma with loss of lung function. At present, only itraconazole and voriconazole are used in the treatment against ABPA and only for patients who are unable to taper oral prednisolone or have an ABPA exacerbation. When an antifungal agent is used, it is only used for 16 weeks. Voriconazole as compared to itraconazole has better gastrointestinal tolerance and bioavailability but skin cancer has been associated with long-term use. TC-PMY-119 has been designed for targeted delivery into the lungs at drastically lower dosage to address the adverse events that can emerge from long-term systemic use.

Esophageal Candidiasis

Esophageal Candidiasis (EC) is the most common type of infectious esophagitis. In the gastrointestinal tract, the esophagus is the second most susceptible to candida infection, only after the oropharynx. Immunocompromised patients are most at risk, including patients with HIV/AIDS, leukemia, diabetics, and those who are receiving corticosteroids, radiation, and chemotherapy. Another group includes those who used antibiotics frequently and those who have esophageal motility disorder (cardiac achalasia and scleroderma). Fluconazole is considered as a first-line agent in EC patients with no other contraindications. However, there have been noted cases of frequent clinical relapses and increased antifungal utilization for prophylaxis reason which are linked to increased risks of antifungal resistance, particularly fluconazole. TC-PMY-121 is being targeted for patients experiencing fluconazole-refractory esophageal candidiasis.

Pulmonary Cryptococcosis

Pulmonary Cryptococcosis (PC) is an invasive fungal infection that is common among organ transplant recipients, and it is challenging to treat among these patients because of their immunocompromised status. Fluconazole is recommended as a first-line treatment modality for pulmonary cryptococcosis in organ transplant recipients. However, cases of fluconazole resistance among Cryptococcus neoformans isolates have been treated successfully with voriconazole. TC-PMY-123 is being targeted for patients with fluconazole-resistant fungal infections., especially for post-transplant patients.